Search by
Industry
Department

Developing a Post-Approval Labeling Risk Management Strategy

Audio conference highlights


Patient injured because of event described in black box warning: Company still liable, long established FDA approved warnings not sufficient...


Patient injured on generic drug: innovator company could be liable for inadequate warnings...


FDA-approved labeling is no longer a regulatory and liability safe zone. Companies face rapidly escalating FDA, product, reimbursement and patent liabilities tied to labeling management. Penalties, damages and fines are hitting billion-dollar-plus levels, with consideration of direct liability for executives being openly discussed. Traditional labeling development and management approaches that center on FDA approval and adverse event reporting are not up to the task of protecting companies and their executives. This audio conference explains what has happened over the last year and likely changes for the coming years and what to do now to position products for success and avoid liability or regulatory disaster.


This audio conference covers:


  • How failure mode & fault tree-type hazard analysis can be applied to labeling development
  • How quantitative risk/frequency assessment can effectively communicate and lower risks
  • Why developing an explicit FDA record on risk & label decisions is essential
  • How adding label engineering methods to the product design space can solve critical risk & regulatory challenges


About the speaker:


Gary Gamerman, MS, JD, is president of Seraphim Life Sciences Consulting, and also a former FDA reviewer and life sciences attorney with 20 years of experience in product research, development, regulatory and liability management, and as an operating executive. He has been involved developing, implementing and accessing labeling engineering and risk management strategies for a wide range of drug and device products for companies, investors and foundations.


Who should attend?


  • Regulatory Affairs
  • Medical Affairs
  • Labeling Managers
  • Marketing
  • Senior Management
  • Risk Management
  • Legal Counsel


*Please note: Each registration covers one line connected to the audio conference. Attendees dialing from separate locations are required to have separate registrations.

Speaker & Time

Gary Gamerman, Seraphim Life Sciences Consulting LLC
Developing a Post-Approval Labeling Risk Management Strategy
Title: President
Duration: 60 minutes
Discount: Buy 2 items, get 25% off your order using coupon code FX25%OFF
Item #: ac20091201
1 Dec 2009 
Registration Price:
$249.00

Order Info

Select Order Type:  
Include Transcript With Order?:  
Quantity
More
Less
 
 
Bookmark and Share reviews

Reviews

Be the first to submit a review on this event!
Rate this item
Similar Events
More about EU Medical Device eLabeling, Compliance & Software Requirements


EU Device Labeling: Issues and Requirements
Dr. Jaap Laufer, Emergo Group Inc.
More about EU Device Labeling: Issues and Requirements


How to Mark & Label Devices Under IEC 60601-1 3rd Edition
Leo Eisner, Eisner Safety Consultants
More about How to Mark & Label Devices Under IEC 60601-1 3rd Edition

 
Recently Viewed
Adaptive Trial Design: Streamlining the Clinical Supply Process
Geert Langendries, Covance IVRS Project Management Group
More about Adaptive Trial Design: Streamlining the Clinical Supply Process


More about Ensuring GCP-Compliant Trials with Clinical Quality Audits


Determining Feasibility in Global Clinical Trials
Kent Thoelke, PRA International
More about Determining Feasibility in Global Clinical Trials


More about Lifecycle Management of the eCTD and NeeS in Europe


An Overview of EMEA & Centralized Procedure
Dr. Ulrich Granzer, Granzer Regulatory Consulting
More about An Overview of EMEA & Centralized Procedure

© Copyright 2010
ForeignExchange Translations.
All rights reserved.

Home  |   FAQ  |   Blog  |   Translation Services  |   Search  |   Privacy Policy  |   Terms of Use  |   Contact Us